Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRβ/B-RAFEric A. Murphy, David A. Cheresh, Jeff Lindquist et al.|Proceedings of the National Academy of Sciences|2010Cited by 59
Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene AlterationsJohn Tyhonas, Stephen W. Kaldor, Lee D. Arnold et al.|Journal of Medicinal Chemistry|2024Cited by 18
Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations.Aleksandra Franovic, Eric S. Martin, Adithi Mohan et al.|Journal of Clinical Oncology|2022Cited by 8